Key Updates and Expert Discussion from Myeloma Rounds (Nurse Practitoner)

Credit Available: AAPA, AANP, ACPE, CABRN, CME

 

Enroll in this Course

FREE

access until November 30, 2025 12:00 am

 

Enroll Now

Activity Description

This webinar will feature highlights from Myeloma Rounds in Durham and Philadelphia that were held in the spring of 2024, as well as highlights of additional clinical updates after the Rounds. Discussion will cover the latest advancements in myeloma, including current and emerging therapies; clinical trials; optimal patient care strategies; disparities and challenges in diagnosis and treatment; and evidence-based treatment approaches. A review of educational resources for you, as well as resources that you can share with your patients will also be provided.

Time to Complete Activity: 1.50 hours

This course is available from:

November 7, 2024 until November 30, 2025

Course Instructors

Edward A. Stadtmauer, MD Speaker

(Chair, Myeloma Rounds, Philadelphia)​ Section Chief, Hematologic Malignancies Roseman, Tarte, Harrow, and Shaffer Families’, President’s Distinguished Professor, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

Cindy Varga, MD Speaker

(Chair, Myeloma Rounds, Winston-Salem) Associate Professor, Atrium Health Levine Cancer Institute, Plasma Cell Dyscrasia Division, Department of Hematology and Oncology, Charlotte, NC

Target Audience

This CE activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with myeloma.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe the latest developments in myeloma, including current and emerging treatments
• Engage patients and caregivers in discussions on clinical trials, newly approved therapies and emerging therapies for myeloma, including combination therapies, CAR T-cell therapy and bispecific antibodies
• Identify disparities and challenges in diagnosis and treatment of myeloma
• Apply evidence-based treatment strategies for optimal patient care
• Access patient support resources
•  

Accreditation, Support and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute Inc, and The Leukemia & Lymphoma Society. Medical Learning Institute Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Medical Learning Institute Inc (MLI) designates this enduring material activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate

Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until October 13, 2025. PAs should only claim credit commensurate with the extent of their participation.

Continuing Pharmacy Education

Medical Learning Institute Inc designates this continuing education activity for 1.50 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-24-076-H01-P
Type of Activity: Application

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.50 continuing education contact hours through the California Board of Registered Nursing.

Nurse Practitioner Continuing Education

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24106941. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change. 

 

Support Statement

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Providers

This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).

Disclosure of Conflicts of Interest Policy

Medical Learning Institute Inc, and The Leukemia & Lymphoma Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.

To that end, MLI & LLS require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI & LLS policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Edward A. Stadtmauer, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: AbbVie, Amgen, Bristol Myers Squibb, Janssen
Research funding: AbbVie

Cindy Varga, MD, has a financial interest/relationship or affiliation in the form of:

The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Arcellx

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc and The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc

For Pharmacists, Medical Learning Institute will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org

About this Activity

Medical Learning Institute Inc and The Leukemia & Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute Inc All Rights Reserved.